MedTrace Logo

Evaluation of Sloan-Charts for Assessment of Disease Progress in Multiple Sclerosis

NCT01272596 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2021-07-29

No results posted yet for this study

Summary

Impairment of visual deficits, in particular contrast acuity and contrast impairment are frequent symptoms in MS. However, visual function is not appropriately covered by the standard tools for clinical assessment, namely, the EDSS and the MSFC.

The primary aim of this study is to investigate, whether in MS patients contrast acuity and sensitivity change over a period of two years.

Secondary aims are the correlation of visual contrast parameters with structural retinal changes and quality of life.

Conditions

Sponsors & Collaborators

  • Novartis Germany GmbH

    collaborator UNKNOWN

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Jan M Dörr, MD · NeuroCure Clinical Research Center, Charité Universitaetsmedizin Berlin

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01272596 on ClinicalTrials.gov